These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30916381)

  • 1. Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab.
    Kimball AB; Kerbusch T; van Aarle F; Kulkarni P; Li Q; Blauvelt A; Papp KA; Reich K; Montgomery D
    Br J Dermatol; 2020 Jan; 182(1):180-189. PubMed ID: 30916381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.
    Reich K; Blauvelt A; Armstrong A; Langley RG; de Vera A; Kolbinger F; Spindeldreher S; Ren M; Bruin G
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1733-1741. PubMed ID: 31009130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
    Reich K; Warren RB; Iversen L; Puig L; Pau-Charles I; Igarashi A; Ohtsuki M; Falqués M; Harmut M; Rozzo S; Lebwohl MG; Cantrell W; Blauvelt A; Thaçi D
    Br J Dermatol; 2020 Mar; 182(3):605-617. PubMed ID: 31218661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
    Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
    Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension.
    Liao K; Mackenzie H; Ait-Oudhia S; Manimaran S; Zeng Y; Akers T; Yun T; de Oliveira Pena J
    Clin Pharmacol Ther; 2024 Mar; 115(3):478-487. PubMed ID: 38012534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis.
    Poulin Y; Ramon M; Rosoph L; Weisman J; Mendelsohn AM; Parno J; Rozzo SJ; Lee P
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1500-1509. PubMed ID: 31919889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
    Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
    Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis.
    Reich K; Jackson K; Ball S; Garces S; Kerr L; Chua L; Muram TM; Blauvelt A
    J Invest Dermatol; 2018 Oct; 138(10):2168-2173. PubMed ID: 29751001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.
    Kimball AB; Papp KA; Reich K; Gooderham M; Li Q; Cichanowitz N; La Rosa C; Blauvelt A
    Br J Dermatol; 2020 Jun; 182(6):1359-1368. PubMed ID: 31487406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine.
    Pederson S; Biondi DM; Allan B; Cady R; Schaeffler B; Baker B; Latham J
    Front Immunol; 2021; 12():765822. PubMed ID: 34759933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
    Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
    Imafuku S; Nakagawa H; Igarashi A; Morita A; Okubo Y; Sano S; Tada Y; Nemoto O; Rozzo SJ; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):844-852. PubMed ID: 33523513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).
    Lebwohl MG; Leonardi CL; Mehta NN; Gottlieb AB; Mendelsohn AM; Parno J; Rozzo SJ; Menter MA
    J Am Acad Dermatol; 2021 Feb; 84(2):398-407. PubMed ID: 32961255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of pembrolizumab in patients with advanced tumors.
    van Vugt MJH; Stone JA; De Greef RHJMM; Snyder ES; Lipka L; Turner DC; Chain A; Lala M; Li M; Robey SH; Kondic AG; De Alwis D; Mayawala K; Jain L; Freshwater T
    J Immunother Cancer; 2019 Aug; 7(1):212. PubMed ID: 31395089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
    Fernandez AP; Dauden E; Gerdes S; Lebwohl MG; Menter MA; Leonardi CL; Gooderham M; Gebauer K; Tada Y; Lacour JP; Bianchi L; Egeberg A; Pau-Charles I; Mendelsohn AM; Rozzo SJ; Mehta NN
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1774-1783. PubMed ID: 35460287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension.
    Yu C; Geng S; Yang B; Deng Y; Li F; Kang X; Bi M; Zhang F; Zhao Y; Pan W; Tian Z; Xu J; Zhang Z; Yu N; Duan X; Guo S; Sun Q; Li W; Tao J; Liu Z; Yin Y; Wang G
    Chin Med J (Engl); 2024 May; 137(10):1190-1198. PubMed ID: 38192233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis.
    Yiu ZZ; Warren RB
    Expert Opin Investig Drugs; 2017 Feb; 26(2):243-249. PubMed ID: 28042732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies.
    Mullins GR; Hodsdon ME; Li YG; Anglin G; Urva S; Schneck K; Bardos JN; Martins RF; Brown K; Calderon B
    J Clin Endocrinol Metab; 2024 Jan; 109(2):361-369. PubMed ID: 37700637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab.
    Passey C; Mora J; Dodge R; Gibiansky L; Sheng J; Roy A; Bello A; Gupta M
    AAPS J; 2017 Mar; 19(2):557-567. PubMed ID: 28070715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.